You're receiving this email because you're subscribed to Ring the Bell from Benzinga. To manage your subscription, click the link at the bottom of this email.

Happy Monday! Whether you’re looking at a red investment portfolio or your fantasy team that’s 0-6 (thank you Christian McCaffrey), sometimes all you need is a win. That was also the case for $BA and $SAVE, two beaten-down names that are finally cleared for takeoff after some positive news. Plus, Chinese stocks are getting hammered again.

—Aaron Bry

Plus, check out the biotech company that’s revolutionizing the way we treat ALS, targeting a $100+ market.

MARKET SNAPSHOT

Last Week: Stocks continued to march higher as earnings from companies like Taiwan Semiconductor and Netflix helped bring the market to new all-time highs.

On Our Radar: More earnings on the way this week with major companies like Tesla set to report. Plus, we’ll hear from a few Fed officials today, and receive initial jobless claims on Thursday.

TOP STORY

Tentative Deal Announced To End Boeing Strike, Union Will Vote Wednesday

What Happened: A preliminary agreement was reached to resolve the five-week strike at Boeing, the troubled aircraft manufacturer. The union informed its 33,000 striking members early Saturday.

So: The International Association of Machinists and Aerospace Workers announced that members will vote on the proposal this Wednesday. Here are the details of the deal, and how much of a raise the machinists are set to receive.

PRESENTED BY NEUROSENSE

NeuroSense Advances Plans For Early Commercialization of Groundbreaking ALS Treatment in Canada, Targeting A $100M+ Market

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases – such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease – recently announced its plans to file for early commercialization approval for PrimeC, the firm’s leading drug candidate designed to synergistically target several biological mechanisms of ALS, under Health Canada’s Notice of Compliance with Conditions (NOC/c) policy. This submission is backed by promising results from the company’s phase 2b ALS PARADIGM clinical trial and supplementary clinical and preclinical data.

Click here to learn more.

FIVE ZINGERS

Analyst Calls: This General Electric spinoff got some bullish analyst coverage this morning, sending shares higher. Here are the other top analyst ratings this week.

What Can’t It Do?: WeGovy’s weight-loss drug received some more positive data in a clinical trial. Is it really a miracle drug?

Watch Out Elon: Toyota Motors is teaming up with Boston Dynamics to take on Tesla’s Optimus humanoid robot.

Don’t Forget The Ketchup: Donald Trump campaigned from a McDonald’s location over the weekend… could the stunt help boost $MCD’s stock?

Your Chance At $30k Risk-Free: Benzinga's World Championship of Trading is about to take off, and all you have to do is sign up and paper trade for your chance at the prizes.

ONE FOR THE ROAD

US-Listed Chinese ETFs Drop After Beijing Cuts Interest Rates

Basically: China’s recent decision to cut interest rates has led to a decline in several China-focused exchange-traded funds (ETFs). The move, aimed at stimulating economic growth, has instead sparked concerns among investors about its broader implications.

What Happened: Several China-focused ETFs experienced declines following the country’s interest rate reduction. Here are the stocks and ETFs getting hit the hardest.

PRESENTED BY BENZINGA

Stay Ahead of the Market with Real-Time Stock Alerts


Get access to the same daily alerts and insights used by top investors, powered by our lightning-fast data feed. Learn how to see the latest alert right here.  

BEFORE YOU GO

Were you forwarded this email? Click here to subscribe.

And be sure to check out our other newsletters:

Future Finance: Where fintech, crypto, and the future of finance collide. Future Finance is a perfect lunch read packed with quick bites for industry enthusiasts. Subscribe here.

Cannabis Daily: A must-read daily briefing for cannabis investors, operators, and enthusiasts. Join our list of industry veterans to jump start your morning. Subscribe here.

Real Estate Weekly: Ready to elevate your real estate game? This weekly newsletter provides actionable insights whether you are investing in REITs, owning property, or delving into the fast-growing world of fractional real estate. Subscribe here.

Advisor: Tailor-made for Financial Advisors, this weekly newsletter has industry-specific insights, analysis, and news. Subscribe here.